CVRx to Report First Quarter 2023 Financial and Operating Results and Host Conference Call on April 27th, 2023

Rhea-AI Summary

CVRx plans to release its first quarter 2023 financial and operational results on April 27, 2023, after market close. The company will host a conference call at 5:00 p.m. Eastern Time that day to discuss these results. Investors can access a live webcast on the investor relations page of CVRx's website. CVRx focuses on developing the Barostim™, a groundbreaking implantable neuromodulation device for cardiovascular diseases, which has received FDA approval and Breakthrough Device designation. Barostim aims to alleviate heart failure symptoms by delivering electrical pulses to baroreceptors in the carotid artery, restoring balance to the autonomic nervous system.

MINNEAPOLIS, April 20, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2023 financial and operating results after market close on Thursday, April 27^th, 2023. The Company will host a conference call to review its results at 5:00 p.m. Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.

About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:
Laura O’Neill
Finn Partners
212-867-1762
laura.oneill@finnpartners.com

FAQ

When will CVRx announce its first quarter 2023 financial results?

CVRx will announce its first quarter 2023 financial and operational results on April 27, 2023, after market close.

What time is the CVRx conference call scheduled for?

The conference call to discuss CVRx's results is scheduled for 5:00 p.m. Eastern Time on April 27, 2023.

How can I listen to the CVRx conference call?

Investors can listen to the conference call by dialing 1-877-704-4453 for U.S. callers or 1-201-389-0920 for international callers, approximately ten minutes before the start time.

What is Barostim and its purpose?

Barostim is an implantable neuromodulation device developed by CVRx, designed to improve symptoms of heart failure by delivering electrical pulses to baroreceptors.

Has Barostim received any regulatory approvals?

Yes, Barostim has received FDA approval and Breakthrough Device designation, as well as CE Mark approval in the European Economic Area.